About Us

TAKE A NEW LEAP FORWARD WITH
INNOVATION TECHNOLOGY

2024

2024.03 MOU with Dongkook pharmaceutical on ‘AI-driven advanced pharmaceutical development’
2024.01 Selected as ‘AI-driven Bio data-based leading technology development project by MIST’
MOU with HLB bioStep on ‘AI drug discovery platform development’ 2023.12
Joint research with SAMJIN PHARM on ‘AI-based innovative drug development’ 2023.10
Selected as ‘Innovative future medical research center by MSIT’ 2023.05
MOU with KMEDI Hub on ‘AI-based patient-customized NCE development’ 2023.05
MOU with FUTURE MEDICINE on ‘AI-Nucleoside NCE platform development’ 2023.05
Presentation of ‘anti-CAF candidates & mechanism’ research results at AACR 2023 2023.04
MOU with NEX-I on ‘AI-based new antibody drug development’ 2023.03

2023

2022

2022.10Launch of AD3
2022.10MOU with SMC on ‘AI-based new drug & RNA cancer vaccine development’
2022.09Selected as ‘industry-University linked new drug development support project by MSIT’
2022.06Selected as ‘AI-based innovative new drug discovery project by MIST’
Series-B investment 2021.12
Joint research with NEURACLE SCIENCE on ‘AI-based innovative drug development’ 2021.12
Selected as ‘2021 National new drug development project by MOHW’ 2021.11
Selected as ‘Digital pathology AI solution development project by MOHW’ 2021.04

2021

2020

2020.11 Series-A investment
2020.01 Joint research with Yonsei University Health System on ‘anti-diabetes drug development’
Joint research with KRICT on ‘anti-cancer drug development’ 2019.12
Selected as ‘2019 AI drug development platform project by MSIT’ 2019.05

2019

2018

2018.10 Company’s name changed to Arontier
2018.02 R&D Center founded
FURAME founded2017.11

2017

MOU with HLB bioStep on ‘AI drug discovery platform development’ 2023.12
Joint research with SAMJIN PHARM on ‘AI-based innovative drug development’ 2023.10
Selected as ‘Innovative future medical research center by MSIT’ 2023.05
MOU with KMEDI Hub on ‘AI-based patient-customized NCE development’ 2023.05
MOU with FUTURE MEDICINE on ‘AI-Nucleoside NCE platform development’ 2023.05
Presentation of ‘anti-CAF candidates & mechanism’ research results at AACR 2023 2023.04
MOU with NEX-I on ‘AI-based new antibody drug development’ 2023.03

2023

2023

2023.12 MOU with HLB bioStep on ‘AI drug discovery platform development’
2023.10 Joint research with SAMJIN PHARM on ‘AI-based innovative drug development’
2023.05 Selected as ‘Innovative future medical research center by MSIT’
2023.05 MOU with KMEDI Hub on ‘AI-based patient-customized NCE development’
2023.05 MOU with FUTURE MEDICINE on ‘AI-Nucleoside NCE platform development’
2023.04 Presentation of ‘anti-CAF candidates & mechanism’ research results at AACR 2023
2023.03 MOU with NEX-I on ‘AI-based new antibody drug development’

2022

2022.10 Launch of AD3
2022.10 MOU with SMC on ‘AI-based new drug & RNA cancer vaccine development’
2022.09 Selected as ‘Industry-University linked new drug development support project by MSIT’
2022.06 Selected as ‘AI-based innovative new drug discovery project by MSIT’

2021

2021.12 Series-B investment
2021.12 Joint research with NEURACLE SCIENCE on ‘AI-based innovative drug development’
2021.11 Selected as ‘2021 National new drug development project by MOHW’
2021.04 Selected as ‘Digital pathology AI solution development project by MOHW’

2020

2020.11 Series-A investment
2020.01 Joint research with Yonsei University Health System on ‘anti-diabetes drug development’

2019

2019.12 Joint research with KRICT on ‘anti-cancer drug development’
2019.05 Selected as ‘2019 AI drug development platform project by MSIT’

2018

2018.10 Company’s name changed to Arontier
2018.02 R&D Center founded

2017

2017.11 FURAME founded
ARONTIER TEL: +82-2-597-0365 | FAX: +82-2-587-0365 | Email: master@arontier.co
ARONTIER TEL: +82-2-597-0365
FAX: +82-2-587-0365
Email: master@arontier.co
ADDRESS : 15F, 241, Gangnam-daero, Seocho-gu, Seoul, Republic of Korea
Copyright 2018~2021 ARONTIER. All Rights Reserved.